Skip to main content
OpenTrials
Completed

NCT Number: NCT05788172

Measuring Menstrual Iron Loss Using the Iron Isotope Dilution Technique

It is very difficult to quantify menstrual blood loss, the reference method is a tedious one. This is a problem, as it is not conducive to objectively measuring menstrual blood loss and understanding the contribution of menstrual iron loss to iron deficiency anemia. With this study, the investigators aim to investigate iron loss during the menstrual cycle and aim to validate a much simpler technique.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Anemia reduction efforts have largely focused on increasing iron intakes such as improving diet quality, food fortification with iron, iron supplementation, biofortification. There is little information on the contribution of menstrual iron loss to iron deficiency anemia.

Indeed, the accurate measurement of menstrual blood loss volume and iron loss is difficult. Self-perception of heavy menstrual blood loss poorly predicts actual blood loss, and the objective measurement of menstrual blood loss remains a tedious method. Various methods have been used to objectively measure menstrual blood loss volume including radioisotopes, but these methods are invasive. The investigators aim to validate a much simpler technique, namely the stable iron isotope dilution methodology. This is a promising new method for quantifying long-term body iron balance, absorption, and loss which has not been applied previously to measure menstrual iron losses. Validating this new method against the alkaline hematin reference method would be an important step to encourage menstrual blood loss measurements and shed light on the contribution of menstrual blood loss to iron deficiency and iron deficiency anemia.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female, 18-30 years old
  • Already labelled with stable iron isotopes at least 12 months prior to study start
  • Weight <70 kg
  • Normal body mass index (18.5 - 25kg/m2)
  • Regular menstrual cycle (self-reported cycle length between 28 and 35 days in the past 6 months)
  • Signed informed consent
  • Able to read and understand English

Exclusion criteria

  • Use of hormonal contraceptives within a 3-month recall period
  • Anemia (hemoglobin < 117 g/L)
  • Any known major metabolic, gastrointestinal, kidney or chronic disease such as diabetes, renal failure, hepatic dysfunction, hepatitis, hypertension, cancer, or cardiovascular diseases (according to the participants own statement)
  • Women with severe menstrual cramps
  • Consumption of iron-containing supplements within 1 month prior to the start of study
  • Known difficulties with blood sampling
  • Pregnancy (serum human chorionic gonadotropin (hCG) < 5 mIU/mL)
  • Current smoking (>1 cigarette per week over a 1-month recall period)
  • Women who are planning to get pregnant
  • Inability to follow the study protocol

Treatment and study plan

Iron isotope dilution

Other

Menstrual blood loss will be determined using the iron isotope dilution technique and compared to the amount determined via the alkaline hematin method.

Alkaline hematin method

Other

Menstrual blood loss will be determined using the alkaline hematin method and compared to the amount determined via the iron isotope dilution technique.

Primary outcomes

  1. Amount of menstrual blood lost (mL/cycle)

    Time frame: At the beginning of menstrual cycle 1 (cycle length between 28 and 35 days)

    The amount of menstrual blood lost will be determined using the alkaline hematin reference method. All sanitary material is collected during menstruation in each cycle and the amount of blood lost is measured directly in this material. For each cycle the total amount of blood lost during this cycle is determined (there will be one value only during each cycle).

  2. Amount of menstrual blood lost (mL/cycle)

    Time frame: At the beginning of menstrual cycle 2 (cycle length between 28 and 35 days)

    The amount of menstrual blood lost will be determined using the alkaline hematin reference method. All sanitary material is collected during menstruation in each cycle and the amount of blood lost is measured directly in this material. For each cycle the total amount of blood lost during this cycle is determined (there will be one value only during each cycle).

  3. Amount of menstrual blood lost (mL/cycle)

    Time frame: At the beginning of menstrual cycle 3 (cycle length between 28 and 35 days)

    The amount of menstrual blood lost will be determined using the alkaline hematin reference method. All sanitary material is collected during menstruation in each cycle and the amount of blood lost is measured directly in this material. For each cycle the total amount of blood lost during this cycle is determined (there will be one value only during each cycle).

  4. Change in isotopic ratio per cycle

    Time frame: Screening, day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78 and 85

    The change in iron losses between the time of menstruation and the remaining duration of the cycle will be measured based on the dilution of the stable iron isotopes in the blood

Secondary outcomes

  1. Hemoglobin concentration (g/L)

    Time frame: Screening, day 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78 and 85

    Hemoglobin will be measured to determine the presence of anemia and for the standardization of menstrual blood loss measurement

  2. Serum ferritin (microg/L)

    Time frame: Day 1 and 85

    Iron status parameter

  3. Serum transferrin receptor (mg/L)

    Time frame: Day 1 and 85

    Iron status parameter

  4. Alpha-1-acid glycoprotein (g/L)

    Time frame: Day 1 and 85

    Chronic inflammation parameter

  5. C-reactive protein (mg/L)

    Time frame: Day 1 and 85

    Acute inflammation parameter

Sponsors and collaborators

Lead sponsor

Isabelle Herter-Aeberli

Other

Collaborators

  • Kamuzu University of Health Sciences
  • Sight and Life Foundation
  • Wageningen University and Research

Registry information

Official study title

Quantifying Menstrual Blood Loss: Validating the Methodology for Stable Iron Isotopes Dilution Against the Alkaline Hematin Method

Acronym: MBL_Loss

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Mar 28, 2023
Registry last updated
Nov 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.